These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 19491080

  • 1. Metabolic and receptor imaging in patients with neuroendocrine tumors: comparison of fludeoxyglucose-positron emission tomography and computed tomography with indium in 111 pentetreotide.
    Zalom ML, Waxman AD, Yu R, Lee J, Ih G, Wolin EM.
    Endocr Pract; 2009; 15(6):521-7. PubMed ID: 19491080
    [Abstract] [Full Text] [Related]

  • 2. Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.
    Shaverdian N, Pinchot SN, Zarebczan B, Gillis HC, Schiro A, Chen H.
    Ann Surg Oncol; 2013 Feb; 20(2):640-5. PubMed ID: 22941169
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. 111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden.
    Hope TA, Calais J, Zhang L, Dieckmann W, Millo C.
    J Nucl Med; 2019 Sep; 60(9):1266-1269. PubMed ID: 30850506
    [Abstract] [Full Text] [Related]

  • 5. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.
    Van Binnebeek S, Vanbilloen B, Baete K, Terwinghe C, Koole M, Mottaghy FM, Clement PM, Mortelmans L, Bogaerts K, Haustermans K, Nackaerts K, Van Cutsem E, Verslype C, Verbruggen A, Deroose CM.
    Eur Radiol; 2016 Mar; 26(3):900-9. PubMed ID: 26162577
    [Abstract] [Full Text] [Related]

  • 6. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
    Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, Pacak K, Marx SJ, Kebebew E.
    J Clin Oncol; 2016 Feb 20; 34(6):588-96. PubMed ID: 26712231
    [Abstract] [Full Text] [Related]

  • 7. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
    Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, Graham M, Sandler MP, Delbeke D, Walker RC.
    J Nucl Med; 2016 May 20; 57(5):708-14. PubMed ID: 26769865
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Incremental diagnostic value and impact on patient management of somatostatin receptor scintigraphy with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors.
    Usmani S, Khan HA, Abdulla M, Ahmed N, abu Huda F, Marafi F, al Kandari F, al Mohannadi S, al Nafisi N.
    Med Princ Pract; 2011 May 20; 20(4):356-61. PubMed ID: 21576997
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. 68Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia.
    El-Maouche D, Sadowski SM, Papadakis GZ, Guthrie L, Cottle-Delisle C, Merkel R, Millo C, Chen CC, Kebebew E, Collins MT.
    J Clin Endocrinol Metab; 2016 Oct 20; 101(10):3575-3581. PubMed ID: 27533306
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical role of fludeoxyglucose (18F) positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with pancreatic neuroendocrine tumors.
    Matsumoto T, Okabe H, Yamashita YI, Yusa T, Itoyama R, Nakao Y, Yamao T, Umzaki N, Tsukamoto M, Kitano Y, Miyata T, Arima K, Nitta H, Hayashi H, Imai K, Chikamoto A, Baba H.
    Surg Today; 2019 Jan 20; 49(1):21-26. PubMed ID: 30128759
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Metastatic gastroenteropancreatic neuroendocrine tumours: 111In-pentetreotide and PET-FDG imaging].
    Serra Arbeloa P, Lancha Hernández C.
    Rev Esp Med Nucl; 2008 Jan 20; 27(3):199-201. PubMed ID: 18570862
    [Abstract] [Full Text] [Related]

  • 20. 111Indium pentetreotide imaging in the evaluation of head and neck tumors.
    Myssiorek D, Tronco G.
    Laryngoscope; 2005 Oct 20; 115(10):1707-16. PubMed ID: 16222183
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.